Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nucresiran in ATTR Amyloidosis With Cardiomyopathy
NCT07052903Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- May 2030
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 36
01
Overview
A Phase 3 trial of nucresiran in transthyretin amyloidosis (ATTR), sponsored by Alnylam Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
nucresiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT07052903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052903.